Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers December 19, 2018
Pharmacy Choice - Pharmaceutical News - Axsome Therapeutics Announces Completion of Patient Enrollment in the ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder - December 19, 2018

Pharmacy News Article

 11/14/18 - Axsome Therapeutics Announces Completion of Patient Enrollment in the ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder

Axsome Therapeutics (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient enrollment in the ASCEND (Assessing Clinical Episodes in Depression) study, a Phase 2 randomized, controlled trial of AXS-05 in major depressive disorder (MDD).

As quoted in the press release:

AXS-05 is a novel, oral, investigational medicine, consisting of dextromethorphan and bupropion, with glutamatergic, monoaminergic, and anti-inflammatory mechanisms. Topline results from the ASCEND trial are expected early January 2019.

We are excited to complete enrollment of the ASCEND trial, and we look forward to the upcoming results of this study. ASCEND is evaluating the effect of AXS-05 as compared to bupropion on the symptoms of major depressive disorder, said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. We believe that the multiple mechanisms of action of AXS-05 may be relevant to other CNS disorders. In addition to major depressive disorder, we are also evaluating AXS-05 in treatment resistant depression with the ongoing STRIDE-1 Phase 3 trial, agitation associated with Alzheimer's disease with the ongoing ADVANCE-1 Phase 2/3 trial, and smoking cessation with a Phase 2 trial that is being conducted under a research collaboration with Duke University.

Click here to read the full press release.

gold outlook free report

Is it a good time to buy gold stocks?


<h5 align="center" class="subheadline">Learn to profit from gold's low price this year!</h5>
Give me my free report!

The post Axsome Therapeutics Announces Completion of Patient Enrollment in the ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder appeared first on Investing News Network.



© 2018 Investing News Network. All Rights Reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Dec 19: Efficacy vs. Safety: Treating BPH & Incontinence in the Elderly
Last Chance
Dec 20: Adult Immunizations: A Guide for Pharmacists, Techs & NPs
Dec 27: Medical Marijuana: The Basic and Clinical Pharmacology, Not The Politics
Jan 02: School is Out! Life is in Session: The Importance of Professional Development in Pharmacy
Jan 03: Management of Bipolar Disorder
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415